- Home
- RVPHW vs FTEK Comparison
RVPHW vs FTEK Comparison
Compare RVPHW & FTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- FTEK
- Stock Information
- Founded
- RVPHW 2018
- FTEK 1987
- Country
- RVPHW United States
- FTEK United States
- Employees
- RVPHW 14
- FTEK N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- FTEK Pollution Control Equipment
- Sector
- RVPHW Health Care
- FTEK Industrials
- Exchange
- RVPHW Nasdaq
- FTEK Nasdaq
- Market Cap
- RVPHW N/A
- FTEK N/A
- IPO Year
- RVPHW N/A
- FTEK N/A
- Fundamental
- Price
- RVPHW $0.05
- FTEK $1.62
- Analyst Decision
- RVPHW
- FTEK Strong Buy
- Analyst Count
- RVPHW 0
- FTEK 1
- Target Price
- RVPHW N/A
- FTEK $4.00
- AVG Volume (30 Days)
- RVPHW 22.4K
- FTEK 439.0K
- Earning Date
- RVPHW 03-14-2025
- FTEK 05-12-2025
- Dividend Yield
- RVPHW N/A
- FTEK N/A
- EPS Growth
- RVPHW N/A
- FTEK N/A
- EPS
- RVPHW N/A
- FTEK N/A
- Revenue
- RVPHW N/A
- FTEK $26,558,000.00
- Revenue This Year
- RVPHW N/A
- FTEK $21.36
- Revenue Next Year
- RVPHW N/A
- FTEK $11.03
- P/E Ratio
- RVPHW N/A
- FTEK N/A
- Revenue Growth
- RVPHW N/A
- FTEK 7.30
- 52 Week Low
- RVPHW $0.13
- FTEK $0.87
- 52 Week High
- RVPHW $0.15
- FTEK $1.80
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- FTEK 67.38
- Support Level
- RVPHW N/A
- FTEK $1.51
- Resistance Level
- RVPHW N/A
- FTEK $1.80
- Average True Range (ATR)
- RVPHW 0.00
- FTEK 0.18
- MACD
- RVPHW 0.00
- FTEK 0.04
- Stochastic Oscillator
- RVPHW 0.00
- FTEK 79.27
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.